Dudediligence.

Definium Therapeutics, Inc

DFTXNASDAQ · Medicinal Chemicals & Botanical Products
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$6,836,487

17 notices · 225,900 sh

Oct 2025 to Oct 2026

Reported ·

$1,358,070

6 sales · 0 buys

Oct 2025 to Jun 2026

The two figures cover different periods.

All 6 reported sales carry the 10b5-1 box. Together they are 0.06% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-09-25: MARK SULLIVAN, Form 1442026-09-25: BRANDI ROBERTS, Form 1442026-09-25: MATTHEW THOMAS WILEY, Form 1442026-09-25: DANIEL ROLLINGS KARLIN, Form 1442026-09-25: ROBERT B BARROW, Form 1442026-09-03: ROBERT B BARROW, Form 1442026-06-25: MARK SULLIVAN, Form 1442026-06-25: MATTHEW THOMAS WILEY, Form 1442026-06-25: BRANDI ROBERTS, Form 1442026-06-25: DANIEL ROLLINGS KARLIN, Form 1442026-06-25: ROBERT B BARROW, Form 1442026-03-25: ROBERT B BARROW, Form 1442026-03-25: DANIEL ROLLINGS KARLIN, Form 1442026-03-25: MARK SULLIVAN, Form 1442025-12-26: Karlin, Dan, Form 1442025-12-26: Sullivan, Mark, Form 1442025-12-26: Barrow, Robert, Form 1442025-12-26: Sullivan Mark, sold2025-12-26: Barrow Robert, sold2025-12-26: Karlin Daniel, sold2026-03-25: Barrow Robert, sold2026-03-25: Sullivan Mark, sold2026-03-25: Karlin Daniel, sold
under a no plan named▼ salesize is dollars

Form 144 notices, newest first

2026-09-25MARK SULLIVAN, Chief Legal Officer$516,093
14,051 shno plan dateForm 4s on file end Jun 23144 ↗
2026-09-25BRANDI ROBERTS, Chief Financial Officer$124,037
3,377 shno plan dateForm 4s on file end Jun 23144 ↗
2026-09-25MATTHEW THOMAS WILEY, Chief Commercial Officer$113,753
3,097 shno plan dateForm 4s on file end Jun 23144 ↗
2026-09-25DANIEL ROLLINGS KARLIN, Chief Medical Officer$398,631
10,853 shno plan dateForm 4s on file end Jun 23144 ↗
2026-09-25ROBERT B BARROW, Chief Executive Officer$1,158,832
31,550 shno plan dateForm 4s on file end Jun 23144 ↗
2026-09-03ROBERT B BARROW, Chief Executive Officer$718,145
19,023 shno plan dateForm 4s on file end Jun 23144 ↗
2026-06-25MARK SULLIVAN, Chief Legal Officer$548,027
13,008 sh10b5-1 plan144 ↗
Form 4, 2026-06-26: sold 13,008 at $45.03 Form 4 ↗
2026-06-25MATTHEW THOMAS WILEY, Chief Commercial Officer$120,787
2,867 sh10b5-1 plan144 ↗
Form 4, 2026-06-26: sold 2,867 at $45.03 Form 4 ↗
2026-06-25BRANDI ROBERTS, Chief Financial Officer$126,938
3,013 sh10b5-1 plan144 ↗
Form 4, 2026-06-26: sold 3,013 at $45.03 Form 4 ↗
2026-06-25DANIEL ROLLINGS KARLIN, Chief Medical Officer$422,775
10,035 sh10b5-1 plan144 ↗
Form 4, 2026-06-26: sold 10,035 at $45.03 Form 4 ↗
2026-06-25ROBERT B BARROW, Chief Executive Officer$1,230,533
29,208 sh10b5-1 plan144 ↗
Form 4, 2026-06-26: sold 29,208 at $45.03 Form 4 ↗
2026-03-25ROBERT B BARROW, Chief Executive Officer$451,241
24,431 sh10b5-1 plan144 ↗
Form 4, 2026-03-26: sold 24,431 at $18.47 Form 4 ↗
2026-03-25DANIEL ROLLINGS KARLIN, Chief Medical Officer$148,092
8,018 sh10b5-1 plan144 ↗
Form 4, 2026-03-26: sold 8,018 at $18.47 Form 4 ↗
2026-03-25MARK SULLIVAN, Chief Legal Officer$197,666
10,702 sh10b5-1 plan144 ↗
Form 4, 2026-03-26: sold 10,702 at $18.47 Form 4 ↗
2025-12-26Karlin, Dan, Chief Medical Officer$73,623
5,600 shplan 2022-06-14144 ↗
Form 4, 2025-12-29: sold 5,600 at $13.15 Form 4 ↗
2025-12-26Sullivan, Mark, Chief Legal Officer$148,244
11,276 shplan 2024-03-14144 ↗
Form 4, 2025-12-29: sold 11,276 at $13.15 Form 4 ↗
2025-12-26Barrow, Robert, Chief Executive Officer$339,072
25,791 shplan 2022-06-15144 ↗
Form 4, 2025-12-29: sold 25,791 at $13.15 Form 4 ↗